Farella Braun + Martel LLP Law Update for February 24, 2016
Preemption Defense: Is Inaction by the FDA Enough? A seeming contradiction between two recent federal district court rulings on preemption and the U.S. Food and Drug Administration’s oversight of pharmaceuticals creates some uncertainty about whether evidence submitted by the drug manufacturer of inaction by the FDA is enough to establish that the FDA would not […]
Continue Reading